Testosterone therapy in glucocorticoid-treated men

Reid, I.R.; Wattie, D.; Evans, Margaret C.; Stapleton, Joanne P.

doi:10.1007/bf02500632

Cited by 35 publications

(48 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were no significant changes in free testosterone, estradiol or PSA (Sun et al 2002). A randomized controlled crossover study in 15 men on long-term glucocorticoid treatment showed an increase in spine bone density of 5% after 12 months treatment with testosterone, whilst no change was observed during the control period of 12 months observation (Reid et al 1996). Side effect and cardiovascular risk factor profiles were acceptable in these small studies, but androgen treatment needs to be more fully explored in a multicentre randomized controlled trial.…”

Section: Treatment Of Osteoporosis In Menmentioning

confidence: 99%

Osteoporosis in the aging male: Treatment options

Tuck

Datta

2008

CIA

View full text Add to dashboard Cite

In elderly women, loss in bone mass and micro-architectural changes are generally attributed to the onset of menopause. Men do not experience menopause, they do, however, experience age-related acceleration in bone loss and micro-architecture deterioration. The incidence of osteoporotic fractures in elderly men, just as in aged women, increases exponentially with age; the rise in men, however, is some 5–10 years later than in women. Up to 50% of male osteoporotics have no identifiable etiology; however elderly males have much higher likelihood of having an identifiable secondary cause than younger men. Therefore, clinical and laboratory evaluation of aged male osteoporotics must be thorough and should be aimed at identifying lifestyle or conditions contributing to bone loss and fragility. It is essential to identify and treat secondary causes and ensure adequate vitamin D and calcium intake before embarking upon treatment with pharmacological agents. The evidence from a limited number of trials suggests that bisphosphonates, especially alendronate and risedronate, are effective in improving BMD, and seem to be the treatments of choice in aged men with osteoporosis. In cases where bisphosphonates are contra-indicated or ineffective, teriparatide or alternatives such as strontium should be considered.

show abstract

Section: Treatment Of Osteoporosis In Menmentioning

confidence: 99%

Osteoporosis in the aging male: Treatment options

Tuck

Datta

2008

CIA

View full text Add to dashboard Cite

show abstract

“…However, in CS treated men, serum testosterone levels are often substantially reduced, and in one study of 15 asthmatic men receiving chronic CS who were treated with testosterone (250 mg/month) or calcium a 5% increase in lumbar BMD over 12 months was observed. 14 Calcitonin has also been studied in patients starting CS and receiving chronic CS, with variable results, and the clinical use of this treatment in CS osteoporosis remains in doubt.…”

Section: Other Treatmentsmentioning

confidence: 99%

How to prevent steroid induced osteoporosis

Sambrook¹

2005

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

“…56 In a trial of testosterone in patients with corticosteroid induced osteoporosis, some of whom were hypogonadal, there was also a significant increase in spinal BMD. 57 There are no studies of the effects of testosterone replacement in patients with chronic liver disease on BMD and the subsequent fracture risk. Although hypogonadism is reported in male cirrhotics with chronic liver disease and male patients with end stage liver disease being assessed for liver transplantation, the overall prevalence is unknown.…”

Section: Testosteronementioning

confidence: 99%